1). Tzianabos AO. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev. 2000. 13:523–33.
Article
2). Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002. 60:258–74.
3). Xiang YZ., Shang HC., Gao XM., Zhang BL. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008. 22:851–8.
Article
4). Robbers JE., Tyler VE. Tyler's Herbs of choice: the therapeutic use of phytomedicinals. New York: Haworth Herbal Press. 1999.
5). Song JY., Han SK., Son EH., Pyo SN., Yun YS., Yi SY. Induction of secretory and tumoricidal activities in peritoneal macrophages by ginsan. Int Immunopharmacol. 2002. 2:857–65.
Article
6). Lim DS., Bae KG., Jung IS., Kim CH., Yun YS., Song JY. Anti-septicaemic effect of polysaccharide from Panax ginseng by macrophage activation. J Infect. 2002. 45:32–8.
7). Dann SM., Eckmann L. Innate immune defenses in the intestinal tract. Curr Opin Gastroenterol. 2007. 23:115–20.
Article
8). Wallace JL., Miller MJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology. 2000. 119:512–20.
Article
9). Playford RJ., Ghosh S. Cytokines and growth factor modulators in intestinal inflammation and repair. J Pathol. 2005. 205:417–25.
Article
10). Mármol F., Sánchez J., López D., Martínez N., Mitjavila MT., Puig-Parellada P. Oxidative stress, nitric oxide and prostaglandin E2 levels in the gastrointestinal tract of aging rats. J Pharm Pharmacol. 2009. 61:201–6.
Article
11). Robert A., Aristoff PA., Wendling MG., Kimball FA., Miller WL Jr., Gorman RR. Cytoprotective and anti-secretory properties of a non-diarrheogenic and non-uterotonic prostacyclin analog: U-68,215. Prostaglandins. 1985. 30:619–49.
12). Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997. 112:1000–16.
Article
13). Lim YH., Na HS., Yun YS., Choi IS., Oh JS., Rhee JH., Cho BH., Lee HC. Suppressive effects of Ginsan on the development of allergic reaction in murine asthmatic model. Int Arch Allergy Immunol. 2009. 150:32–42.
Article
14). Linkous DA., Oliver JD. Pathogenesis of Vibrio vulnificus. FEMS Microbiol Lett. 1999. 174:207–14.
15). Han SK., Song JY., Yun YS., Yi SY. Ginsan improved Th1 immune response inhibited by gamma radiation. Arch Pharm Res. 2005. 28:343–50.
Article
16). Ahn JY., Choi IS., Shim JY., Yun EK., Yun YS., Jeong G., Song JY. The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur J Immunol. 2006. 36:37–45.
Article
17). Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005. 133:383–91.
18). Hor LI., Chang YK., Chang CC., Lei HY., Ou JT. Mechanism of high susceptibility of iron-overloaded mouse to Vibrio vulnificus infection. Microbiol Immunol. 2000. 44:871–8.
19). Park HS., Francis KP., Yu J., Cleary PP. Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J Immunol. 2003. 171:2532–7.
Article
20). Hyland KA., Brennan R., Olmsted SB., Rojas E., Murphy E., Wang B., Cleary PP. The early interferon response of nasal-associated lymphoid tissue to Streptococcus pyogenes infection. FEMS Immunol Med Microbiol. 2009. 55:422–31.
21). Kiyono H., Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol. 2004. 4:699–710.
22). Smith WL., Dewitt DL. Prostaglandin endoperoxide H synthases-1 and −2. Adv Immunol. 1996. 62:167–215.
Article
23). Sales KJ., Katz AA., Howard B., Soeters RP., Millar RP., Jabbour HN. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002. 62:424–32.